Age-related macular degeneration and cancer mortality in the atherosclerosis risk in communities study

Archives of Ophthalmology

Volumn 125, Issue 9, 2007, Pages 1241-1247

  Cheung, Ning ^a,b   Shankar, Anoop ^c   Klein, Ronald ^e   Folsom, Aaron R ^f   Couper, David J ^g   Wong, Tien Yin ^a,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ATHEROSCLEROSIS; CANCER MORTALITY; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNIC GROUP; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; RISK FACTOR;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ATHEROSCLEROSIS; CAUSE OF DEATH; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 34548620610     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.9.1241     Document Type: Article

References (42)

1. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med. 2000;342(7):483-492.
2. Clemons TE, Kurinij N, Sperduto RD. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13. Arch Ophthalmol. 2004;122(5):716-726.
3. Taylor HR, McCarty CA, Nanjan MB. Vision impairment predicts five-year mortality. Trans Am Ophthalmol Soc. 2000;98:91-96, discussion 96-99.
4. Buch H, Vinding T, la Cour M, Jensen GB, Prause JU, Nielsen NV. Age-related maculopathy: a risk indicator for poorer survival in women: the Copenhagen City Eye Study. Ophthalmology. 2005;112(2):305-312.
5. Klein R, Klein BE, Moss SE. Age-related eye disease and survival: the Beaver Dam Eye Study. Arch Ophthalmol. 1995;113(3):333-339.
6. Borger PH, van Leeuwen R, Hulsman CA, et al. Is there a direct association between age-related eye diseases and mortality? the Rotterdam Study. Ophthalmology. 2003;110(7):1292-1296.
7. Thiagarajan M, Evans JR, Smeeth L, Wormald RP, Fletcher AE. Cause-specific visual impairment and mortality: results from a population-based study of older people in the United Kingdom. Arch Ophthalmol. 2005;123(10):1397-1403.
8. Wong TY, Klein R, Sun C, et al. Age-related macular degeneration and risk for stroke. Ann Intern Med. 2006;145(2):98-106.
9. Voutilainen-Kaunisto RM, Terasvirta ME, Uusitupa MI, Niskanen LK. Age-related macular degeneration in newly diagnosed type 2 diabetic patients and control subjects: a 10-year follow-up on evolution, risk factors, and prognostic significance. Diabetes Care. 2000;23(11):1672-1678.
10. Knudtson MD, Klein BE, Klein R. Age-related eye disease, visual impairment, and survival: the Beaver Dam Eye Study. Arch Ophthalmol. 2006;124(2):243-249.
11. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385-389.
12. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308(5720):421-424.
13. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308(5720):419-421.
14. Zareparsi S, Branham KE, Li M, et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet. 2005;77(1):149-153.
15. Magnusson KP, Duan S, Sigurdsson H, et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med. 2006;3(1):e5. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid= 16300415. Accessed June 28, 2007.
16. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102(20):7227-7232.
17. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20(6):705-732.
18. Spaide RF, Armstrong D, Browne R. Continuing medical education review: choroidal neovascularization in age-related macular degeneration - what is the cause? Retina. 2003;23(5):595-614.
19. Kalayoglu MV, Galvan C, Mahdi OS, Byrne GI, Mansour S. Serological association between Chlamydia pneumoniae infection and age-related macular degeneration. Arch Ophthalmol. 2003;121(4):478-482.
20. Robman L, Mahdi O, McCarty C, et al. Exposure to Chlamydia pneumoniae infection and progression of age-related macular degeneration. Am J Epidemiol. 2005;161(11):1013-1019.
21. Ajona D, Castano Z, Garayoa M, et al. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res. 2004;64(17):6310-6318.
22. Junnikkala S, Hakulinen J, Jarva H, et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer. 2002;87(10):1119-1127.
23. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366(9499):1784-1793.
24. Kovacic P, Jacintho JD. Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr Med Chem. 2001;8(7):773-796.
25. Cerutti PA, Trump BF. Inflammation and oxidative stress in carcinogenesis. Cancer Cells. 1991;3(1):1-7.
26. Littman AJ, Jackson LA, Vaughan TL. Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev. 2005;14(4):773-778.
27. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives: the ARIC investigators. Am J Epidemiol. 1989;129(4):687-702.
28. Jackson R, Chambless LE, Yang K, et al. Differences between respondents and nonrespondents in a multicenter community-based study vary by gender ethnicity: the Atherosclerosis Risk in Communities (ARIC) Study Investigators. J Clin Epidemiol. 1996;49(12):1441-1446.
29. Klein R, Clegg L, Cooper LS, et al. Prevalence of age-related maculopathy in the Atherosclerosis Risk in Communities Study. Arch Ophthalmol. 1999;117(9):1203-1210.
30. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98(7):1128-1134.
31. National Heart, Lung, and Blood Institute. Atherosclerosis Risk in Communities Study. Operations Manual No. 2, Cohort Component Procedures, Version 2.0. Chapel Hill: ARIC Coordinating Center, School of Public Health, University of North Carolina, Chapel Hill; 1988.
32. Hastie T, Tibshirani R. Generalized Additive Models. London, England: Chapman & Hall; 1990.
33. Figueiras A, Cadarso-Suarez C. Application of nonparametric models for calculating odds ratios and their confidence intervals for continuous exposures. Am J Epidemiol. 2001;154(3):264-275.
34. Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR. Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Ophthalmology. 2007;114(1):86-91.
35. Klein R, Klein BE, Moss SE, Cruickshanks KJ. Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol. 1999;117(11):1487-1495.
36. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-545.
37. Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis. 2002;19(3):247-258.
38. Cheng ZZ, Corey MJ, Parepalo M, et al. Complement factor H as a marker for detection of bladder cancer. Clin Chem. 2005;51(5):856-863.
39. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol. 2006;141(1):149-156.
40. Borrell LN, Diez Roux AV, Rose K, Catellier D, Clark BL. Neighbourhood characteristics and mortality in the Atherosclerosis Risk in Communities Study. Int J Epidemiol. 2004;33(2):398-407.
41. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006;24(9):1342-1349.
42. Klein R, Meuer SM, Moss SE, Klein BE. Detection of drusen and early signs of age-related maculopathy using a nonmydriatic camera and a standard fundus camera. Ophthalmology. 1992;99(11):1686-1692.